July 17, 2026
REVILICO HAS SUCCESSFULLY RAISED ITS SEED ROUND
REVILICO HAS SUCCESSFULLY RAISED ITS SEED ROUND
July 17, 2026 REVILICO HAS SUCCESSFULLY RAISED ITS SEED ROUND ❮ ❯ Revilico, a US-based startup, is building an end-to-end AI operating system for pharma R&D, connecting computational chemistry, biology, AI, and lab validation in one platform. Led by Lebanese co-founder and CEO Christopher Korban, the startup is backed by investors including Forum Ventures and […]
Revilico, a US-based startup, is building an end-to-end AI operating system for pharma R&D, connecting computational chemistry, biology, AI, and lab validation in one platform. Led by Lebanese co-founder and CEO Christopher Korban, the startup is backed by investors including Forum Ventures and Mighty Capital, with participation from IM Ventures.
Founded in 2024 by Christopher Korban and Christian Chung, Revilico helps pharma, biotech, and research teams accelerate drug discovery by bringing drug design, computational simulation, biological modeling, and lab testing into one connected workflow.
At IM Ventures, we see strong potential in Revilico’s team, differentiated AI + physics-based approach, and vision to become a broader operating system for pharma R&D. The company has demonstrated strong early commercial validation and growing adoption across pharma, biotech, and research institutions.